iSpecimen Inc. (ISPC)
NASDAQ: ISPC · Real-Time Price · USD
1.330
-0.020 (-1.48%)
At close: Sep 18, 2026, 4:00 PM EDT
1.340
+0.010 (0.75%)
After-hours: Sep 18, 2026, 7:37 PM EDT
iSpecimen Revenue
iSpecimen had revenue of $151.94K in the quarter ending June 30, 2026, a decrease of -78.69%. This brings the company's revenue in the last twelve months to $466.30K, down -92.11% year-over-year. In the year 2025, iSpecimen had annual revenue of $1.93M, down -79.24%.
Revenue (ttm)
$466.30K
Revenue Growth
-92.11%
P/S Ratio
7.18
Revenue / Employee
$66,615
Employees
7
Market Cap
3.35M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.93M | -7.36M | -79.24% |
| Dec 31, 2024 | 9.29M | -637.07K | -6.42% |
| Dec 31, 2023 | 9.93M | -474.12K | -4.56% |
| Dec 31, 2022 | 10.40M | -733.00K | -6.58% |
| Dec 31, 2021 | 11.14M | 2.95M | 36.06% |
| Dec 31, 2020 | 8.18M | 3.89M | 90.40% |
| Dec 31, 2019 | 4.30M | -96.47K | -2.20% |
| Dec 31, 2018 | 4.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MDxHealth | 114.02M |
| Biodesix | 102.94M |
| Burning Rock Biotech | 73.70M |
| Exagen | 71.12M |
| XWELL | 28.28M |
| Precipio | 27.20M |
| bioAffinity Technologies | 5.90M |
| Insight Molecular Diagnostics | 1.67M |
ISPC News
- 6 days ago - iSpecimen Proxy statement: Proxy filing - Filings
- 16 days ago - iSpecimen Proxy statement: Proxy filing - Filings
- 4 weeks ago - iSpecimen completes international cancer research project - TheFly
- 4 weeks ago - iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks - GlobeNewsWire
- 5 weeks ago - iSpecimen Quarterly report: Q2 2026 - Filings
- 6 weeks ago - iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 6 weeks ago - E.F. Hutton & Co. Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen - GlobeNewsWire
- 6 weeks ago - E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen - GlobeNewsWire